RXST RxSight Inc.

Biotech Analyst Ratings

Latest News

1. 05 May 2022 RxSight, Inc. Reports First Quarter 2022 Financial Results

   ALISO VIEJO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today reported financial results for the three months ended March 31, 2022.
   

   Key Quarterly Highlights:

   • Delivered first quarter 2022 revenue of $8.9 million, an increase of 157% compared to the first quarter of 2021, reflecting:
     • The sale of 40 Light Delivery Devices (LDD™s), representing a 208% unit increase from the first quarter of 2021, expanding the installed base to 246 LDDs at the end of the quarter, a 134% increase compared to the 105 LDD installed base at the end of the first quarter of 2021.
     • The sale of 4,166 Light Adjustable Lenses (LAL®s…

   View Full Article
2. 19 April 2022 Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting

   ALISO VIEJO, Calif. , April 19, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that its Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens^® (LAL^®), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various surgeon presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Washington D.C. on April 22-26, 2022.   
   

   The following are posters and papers accepted for presentation:

   Friday, April 22:

   Evaluation of Clinical Outcomes after Implantation of an IOL That Can Be Optimized with UV Light Compared to an Extended …

   View Full Article